Clinical Trial Update: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating evofosfamide (TH-302) in combination with pemetrexed versus placebo in non-squamous non-small cell lung cancer was terminated. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Evofosfamide (evofosfamide)

Snippet

Sponsor: ImmunoGenesis | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-08-11